Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

34.47
-0.2200-0.63%
Post-market: 34.470.00000.00%19:53 EST
Volume:7.55M
Turnover:260.20M
Market Cap:39.55B
PE:28.49
High:34.63
Open:34.57
Low:34.27
Close:34.69
52wk High:37.35
52wk Low:12.47
Shares:1.15B
Float Shares:1.14B
Volume Ratio:0.53
T/O Rate:0.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.21
EPS(LYR):1.21
ROE:20.79%
ROA:6.17%
PB:5.00
PE(LYR):28.49

Loading ...

Teva Pharmaceuticals Is Maintained at Buy by Goldman Sachs

Dow Jones
·
11 hours ago

Teva price target raised to $45 from $36 at Goldman Sachs

TIPRANKS
·
Yesterday

Teva’s Sustainability Disclosures Face Rising Legal and Investor Risk Amid Global Compliance Demands

TIPRANKS
·
Feb 04

The Druckenmiller Connection: Meet the Man Behind Bessent and Warsh -- Barrons.com

Dow Jones
·
Feb 02

Teva (TEVA) Is Up 7.1% After 2025 Earnings Highlight Branded-Drugs Momentum And Pipeline Progress

Simply Wall St.
·
Feb 01

Is Teva Pharmaceutical Industries (TEVA) Still Attractive After A 92% One-Year Share Price Surge

Simply Wall St.
·
Jan 31

Teva Pharmaceuticals Is Maintained at Overweight by Barclays

Dow Jones
·
Jan 31

Teva price target raised to $38 from $35 at Barclays

TIPRANKS
·
Jan 30

Analysts Offer Insights on Healthcare Companies: Resmed (RMD), Waters (WAT) and Teva Pharmaceutical (TEVA)

TIPRANKS
·
Jan 30

Teva Pharmaceuticals : UBS Raises Target Price to $39 From $37

THOMSON REUTERS
·
Jan 30

Teva Pharmaceuticals Is Maintained at Buy by Truist Securities

Dow Jones
·
Jan 29

Teva price target raised to $40 from $35 at Scotiabank

TIPRANKS
·
Jan 29

Truist Raises Price Target on Teva Pharmaceutical Industries to $38 From $36, Keeps Buy Rating

MT Newswires Live
·
Jan 29

Teva Pharmaceutical (TEVA) Receives a Buy from Truist Financial

TIPRANKS
·
Jan 29

Teva Earnings Call: Innovation Offsets Generics and One-Offs

TIPRANKS
·
Jan 29

Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook

Benzinga
·
Jan 29

Teva says targeting FY26 gross margin of 54.5%-55.5%

TIPRANKS
·
Jan 28

Teva reports Q4 non-GAAP EPS 96c, consensus 64c

TIPRANKS
·
Jan 28

Stock Track | Teva Pharmaceutical Plunges 8.08% in Pre-Market on Disappointing 2026 Guidance

Stock Track
·
Jan 28

GUIDANCE: (TEVA) Teva Pharmaceutical Expects Full Year 2026 Non-GAAP EPS Range $2.57 - $2.77, vs. FactSet Est of $2.81

MT Newswires Live
·
Jan 28